Nikhil Narang, MD
@Nikhil15
Followers
3K
Following
17K
Media
566
Statuses
4K
HF/Transplant/LVAD • Dad • #JACCHF #SoMe Team @JACCJournals
Chicago, IL
Joined October 2008
What is the burden of VAD related AE’s in pts w/ HM3 VAD w/ and w/out temp RVAD?. At 1-Yr:.⬆️ mortality .⬆️ risk of dialysis .⬆️ stroke (propensity matched) .🟰 risk GIB, infection, VT. Our large Advocate experience now in @ESCHeartFailure . 📎
2
10
33
RT @manreetkanwar: we all try to recover our cardiogenic shock pts with temp MCS devices, esp Impella 5.5. Here is our standardized approac….
0
21
0
An end to 6 years with the oustanding ACMC @advocatehealth team, cannot be more thankful for the friendship, team-work, always picking each other up. An incredible team and group. Thank you thank you thank you💙. @SPauwaa @VQChau20 @MarkDLC_MD @gmac78 @DrJessP_MD @lacoyle78
3
2
40
RT @NirUrielMD: Our @CU_Cardiology experience with letermovir prophy for mod/high risk CMV post-OHT, a promising new therapy to avoid the t….
0
8
0
RT @ankeetbhatt: Fantastic #CKM health review by @Deoliveiragdc @vbluml on the intersection of renal failure & cardiogenic shock. https://….
0
15
0
RT @AndrewPAmbrosy: AF and HFpEF co-exist and drive CV risk. Managing AF in HFpEF requires an integrated approach—HF therapy, rhythm or rat….
0
6
0
RT @EMDeFilippisMD: Excited to share our UNOS analysis analyzing sex differences in the use of #DCD donors for HT now published in @CircHF.
0
2
0
RT @FudimMarat: New tech alert! A wearable sensor (CardioTag) + advanced ML model estimates Pulmonary Capillary Wedge Pressure, key for hea….
0
43
0
RT @AndrewJSauer: 🚨Two new JACC Advances papers drop today linking SGLT2 inhibitors ↔ apolipoprotein M (ApoM) across very different setting….
0
55
0
RT @haiderwarraich: Many clinicians tell patients to avoid social media yet our new research shows what an incredible impact social media c….
0
11
0
Some great VAD resources for new #ACCFIT trainees . Management of VAD: . Prevent RV failure: @JonGrinsteinMD @KanelidisMD . VAD SOA: @RyanTedfordMD . Newest INTERMACS @manreetkanwar.
1
7
17
✅ Risk of tRVAD in HM3 very high during index admission though 1yr mortality risk post-discharge for survivors is reasonable (11%) . ✅ Factors to predict RV failure remain somewhat unpredictable though totality of risk re: tRVAD need in contemporary era needs to be weighed.
1
0
2
51 pts w/tRVAD out of 192 HM3. ✅49% INTERMACS 1 or 2 in tRVAD vs. 27% in HM3 alone. ✅ pre-op VA-ECMO 28% tRVAD vs. 5% in HM3 alone . 🟰pre-op HM3 Risk Scores similar between groups . No 🔼 in mortality in delayed vs. up-front tRVAD
1
0
3
RT @JanBiegus: 👋 Dear Colleagues and Friends,.Please take 5 minutes ⏳ to complete the survey on HF pharmacotherapy 💊❤️. Every response is h….
0
10
0
Relavent and outstanding @HFSA position statement by @amorrismd @KevinShahMD @NMHheartdoc on the Impact of health care disparities on patients living with heart failure in @JCardFail .
0
0
4
Follow-up to paper by @jrbertot @mvaduganathan @SunnyVMD @ankeetbhatt in @JCardFail IMPLEMENT-HF study where virtual care GDMT optimization was less effective in Hispanic pts vs non-Hispanic patients .
1
1
4
We are in a “golden-era”of GDMT .for pts w/ HFrEF, what barriers do we face in 25’ in implementation? . Should strategies be dynamic by race/age/SE background?. Our editorial in @JCardFail by @UCCardsFellows Mary Acosta @manreetkanwar explores this❓. 📎
2
16
37
RT @AndrewJSauer: New real-world evidence out in @JCardFail ! 👇. In 503 NYHA III HFrEF pts treated with #CardiacContractilityModulation,….
0
14
0